Epilepsy Research and Treatment

Research Article

Executive Functions in Chronic Mesial Temporal Lobe Epilepsy

Table 4

Individual daily dose and serum level of the antiepileptic drug therapy.
Patient codeGenderAgeEducationAED daily dose (mg)AED serum level (μg/ml)Outlier
P 1m3510PGB 600, PB 150PGB 6.3, PB 11.1
P 2m3410LEV 2000, PHE 200LEV 9.2, PHE 3.2
P 3f4610LTG 150, LEV 2000LTG 2.0, LEV 27.4a
P 4f489LTG 400, PRM 500, ZNS 200LTG 9.5, PB 12.0, PRM 10.4, ZNS 18.6b, c, d
P 5m499CBZ RD 1050CBZ 3.8, CBZ Epoxid 0.6
P 6f4412CBZ RD 600CBZ 7.7
P 7m4610CBZ 300CBZ 3.4
P 8m2013OXC 900OXC 0.4, 10-OH-Carbazepin 24.6
P 9m4410OXC 900, LEV 3000OXC 0.2, 10-OH-Carbazepin 13.2, LEV 27.0
P 10f4610LEV 3000LEV 47.9e
P 11m3713CBZ 300CBZ 0.0
P 12m3313CBZ RD 1200CBZ 7.9
P 13m5910CBZ RD 200CBZ 1.7, CBZ Epoxid 0.1d, f
P 14m519CBZ RD 1200, TPM 250CBZ 10.1, TPM 4.5
P 15f2410CBZ 750CBZ 8.6a
P 16f549LEV 1500LEV 28.8
P 17m5810CBZ RD 800, ZNS 200CBZ 10.1, CBZ Epoxid 1.2, ZNS 5.4
P 18f509LEV 2000LEV 32
P 19f1812LEV 3000, VPA RD 1250, ZNS 300LEV 70.3, VPA 111.7, ZNS 22.4
P 20m3810LTG 300, PHE 200LTG 3.9, PHE 5.4
P 21f3610LTG 200LTG 10.7
P 22m2416LEV 3000, PGB 300LEV 43.8, PGB 3.9
P 23m2910LEV 3000, PHE 400LEV 27.5, PHE 19.9
P 24f3513CBZ RD 600CBZ 5.8
P 25m5710CBZ RD 400, LEV 3000CBZ 5.4, CBZ Epoxid 0.9, LEV 38.2
P 26m4310LEV 4000, OXC 2100LEV 23.8, OXC 0.0, 10-OH-Carbazepin 24.3
P 27f3010LEV 1000LEV 3.4
P 28f409CBZ RD 1400CBZ 12.2
AED: antiepileptic drug; m: male; f: female; CBZ: carbamazepine; LTG: lamotrigine; LEV: levetiracetam; OXC: oxcarbazepine; PB: phenobarbital; PHE: phenytoin; PGB: pregabalin; PRM: primidone; TPM: topiramate; VPA: valproate; ZNS: zonisamide; a: outlier performance in planning (total number of moves or errors, Planungstest); b: outlier performance in categorical verbal fluency (animals/min, RWT); c: outlier performance in categorization (perseverative errors, WCST); d: outlier performance in verbal memory (recognition, MGT); e: outlier performance in verbal attention (digit span forward, WMS-R); f: outlier performance in inhibitory control (correct NoGo trials, Go-NoGo task).